1. Academic Validation
  2. Early clinical heterogeneity in choreoacanthocytosis

Early clinical heterogeneity in choreoacanthocytosis

  • Arch Neurol. 2005 Apr;62(4):611-4. doi: 10.1001/archneur.62.4.611.
Alexander Lossos 1 Carol Dobson-Stone Anthony P Monaco Dov Soffer Ezra Rahamim J P Newman Saidi Mohiddin Lameh Fananapazir Israela Lerer Eduard Linetsky Avinoam Reches Zohar Argov Oded Abramsky Natan Gadoth Menachem Sadeh John M Gomori Moshe Boher Vardiella Meiner
Affiliations

Affiliation

  • 1 Department of Neurology, Hadassah-Hebrew Unviersity Hospital, Jerusalem, Israel. alos@hadassah.org.il
Abstract

Background: Choreoacanthocytosis (CHAC) is a slowly progressive multisystem disorder with involuntary movements, cognitive decline, behavioral changes, seizures, and polyneuropathy caused by mutations in the VPS13A gene.

Objective: To describe the early clinical features and possible genotype-phenotype correlation in CHAC.

Design and setting: Case series in a tertiary care center. PATIENTS AND MAIN OUTCOME METHODS: Choreoacanthocytosis was diagnosed in 3 patients of Jewish origin from 3 unrelated families. We reviewed their medical histories and performed molecular analysis by screening all 73 exons of VPS13A.

Results: Trichotillomania, hypertrophic cardiomyopathy, and idiopathic hyperCKemia, in 1 patient each, preceded the development of the full clinical spectrum of CHAC by 2 to 20 years. At diagnosis, 2 patients manifested signs of overt neuromuscular involvement and were homozygous for the 6059delC mutation, whereas 1 patient had only hyporeflexia and was homozygous for the EX23del mutation. Because only 1 of the 2 patients with 6059delC had cardiomyopathy, its relevance to CHAC is unclear.

Conclusions: These findings extend the knowledge of significant early clinical heterogeneity in CHAC and suggest a possible genotype-phenotype correlation. Awareness of the early manifestations may prevent misdiagnosis and enable appropriate genetic counseling.

Figures